Yahuilong announced on August 17 that the company recently received medical device registration certificates issued by the Guangdong Medical Products Administration for two microfluidic chemiluminescence testing instruments. The certified instruments are part of the company's research task as the lead unit for the national key research and development program under the 14th Five-Year Plan, specifically the key project on high-performance rapid on-site immunoassay system development within diagnostic and therapeutic equipment and biomedical materials. These certified instruments represent a phased achievement in the company's research and development of cutting-edge microfluidic biological detection technology, and are compatible with six microfluidic chemiluminescence testing reagents for which the company obtained certification in July 2026, helping to further enhance the company's core competitiveness. In the first quarter of 2026, Yahuilong achieved revenue of 398 million yuan and net profit attributable to the parent company of 17.95 million yuan.
Shenzhen YHLO Biotech Co. Ltd. AReceived medical device registration certificates for two new microfluidic chemiluminescence testing instruments, a phased R&D achievement.
